Melanoma

  • ECOG E3611- A Phase II Randomized Study of Ipilimumab at 3mg/kg or 10mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma
  • ECOG E3612- A Phase II Randomized Study of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • SWOG S1320- A Phase II Randomized Study of Intermittent Versus Continous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma